USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.
EZH2
USP21
cell proliferation
deubiquitination
diffuse large B-cell lymphoma
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
revised:
14
12
2020
received:
10
11
2020
accepted:
17
12
2020
pubmed:
4
1
2021
medline:
5
11
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
Diffuse large B-cell lymphoma (DLBCL) is the most common category of non-Hodgkin lymphoma (NHL). However, the underlying molecular mechanism of DLBCL remains unclear. Real-time PCR and Western blot analysis were performed to assess the expression of ubiquitin-specific peptidase 21 (USP21) or enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2). CCK8 assay and cell death staining were carried out to examine the role of USP21 in cell proliferation and cell death, respectively. We found that the deubiquitinase USP21 was highly expressed in the DLBCL lymphoid tissue. The expression of USP21 promoted DLBCL cell proliferation, while it had no obvious effect on cell death. In addition, we found that USP21 regulated cell proliferation via cysteine 221, the catalytic site of USP21. Furthermore, we identified that USP21 could stabilize EZH2, a protein required for germinal center formation and lymphoma formation. The deubiquitinase USP21 promotes cell proliferation by maintaining the EZH2 protein level in DLBCL.
Sections du résumé
BACKGROUND
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is the most common category of non-Hodgkin lymphoma (NHL). However, the underlying molecular mechanism of DLBCL remains unclear.
METHODS
METHODS
Real-time PCR and Western blot analysis were performed to assess the expression of ubiquitin-specific peptidase 21 (USP21) or enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2). CCK8 assay and cell death staining were carried out to examine the role of USP21 in cell proliferation and cell death, respectively.
RESULTS
RESULTS
We found that the deubiquitinase USP21 was highly expressed in the DLBCL lymphoid tissue. The expression of USP21 promoted DLBCL cell proliferation, while it had no obvious effect on cell death. In addition, we found that USP21 regulated cell proliferation via cysteine 221, the catalytic site of USP21. Furthermore, we identified that USP21 could stabilize EZH2, a protein required for germinal center formation and lymphoma formation.
CONCLUSION
CONCLUSIONS
The deubiquitinase USP21 promotes cell proliferation by maintaining the EZH2 protein level in DLBCL.
Identifiants
pubmed: 33389794
doi: 10.1002/jcla.23693
pmc: PMC7957995
doi:
Substances chimiques
USP21 protein, human
0
EZH2 protein, human
EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
Ubiquitin Thiolesterase
EC 3.4.19.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23693Subventions
Organisme : National Natural Science Foundation of China
ID : 31701209
Informations de copyright
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Exp Cell Res. 2011 May 1;317(8):1179-91
pubmed: 21324313
Protein Cell. 2020 Nov;11(11):852-857
pubmed: 32607788
J Clin Oncol. 2014 Nov 1;32(31):3506-12
pubmed: 25267745
Curr Hematol Malig Rep. 2018 Oct;13(5):369-382
pubmed: 30112706
Blood. 2018 May 10;131(19):2125-2137
pubmed: 29572378
Theranostics. 2018 Apr 18;8(11):2927-2938
pubmed: 29896294
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Cell Rep. 2019 Mar 12;26(11):3076-3086.e6
pubmed: 30865895
Cancer Metastasis Rev. 2017 Dec;36(4):635-653
pubmed: 29134486
Mol Biol Cell. 2012 Mar;23(6):1095-103
pubmed: 22298430
Signal Transduct Target Ther. 2016 Nov 04;1:16024
pubmed: 29263902
J Cell Physiol. 2019 Jun;234(6):9723-9732
pubmed: 30362575
Blood. 2019 Oct 17;134(16):1289-1297
pubmed: 31350266
Nat Commun. 2015 Sep 30;6:8471
pubmed: 26419610
Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71
pubmed: 23375551
Curr Treat Options Oncol. 2018 Jun 21;19(8):38
pubmed: 29931605
Exp Cell Res. 2016 Aug 15;346(2):157-66
pubmed: 27397581
Oncotarget. 2016 Jul 5;7(27):42007-42016
pubmed: 27259257
Cancer Metastasis Rev. 2016 Dec;35(4):589-600
pubmed: 27844253
Exp Cell Res. 2020 Oct 1;395(1):112188
pubmed: 32707136
Nat Commun. 2016 Nov 25;7:13594
pubmed: 27886188
Cell Res. 2019 Feb;29(2):171-173
pubmed: 30429527
Thorac Cancer. 2018 May;9(5):630-639
pubmed: 29577649
Onco Targets Ther. 2017 Feb 07;10:681-689
pubmed: 28223825
Br J Haematol. 2013 Oct;163(1):123-6
pubmed: 23795711
J Genet Genomics. 2019 Dec 20;46(12):591-594
pubmed: 31952940
J Clin Lab Anal. 2020 Nov;34(11):e23462
pubmed: 32691951
Int J Mol Sci. 2020 Apr 06;21(7):
pubmed: 32268558
J Biol Chem. 2020 Oct 16;295(42):14343-14351
pubmed: 32796032
Theranostics. 2017 Feb 23;7(4):1002-1009
pubmed: 28382171
Signal Transduct Target Ther. 2020 Jun 19;5(1):79
pubmed: 32555175
Cell. 2005 Dec 2;123(5):773-86
pubmed: 16325574
Expert Opin Ther Pat. 2015;25(10):1191-1208
pubmed: 26077642
Asia Pac J Clin Oncol. 2020 Oct 13;:
pubmed: 33052017
APMIS. 2020 Apr;128(4):308-315
pubmed: 31991488
Nat Med. 2012 Feb 19;18(3):429-35
pubmed: 22344298
Blood. 2010 Nov 11;116(19):3724-34
pubmed: 20664057
Dev Cell. 2020 May 4;53(3):287-299.e5
pubmed: 32275885
Front Pharmacol. 2020 Jun 26;11:971
pubmed: 32676030
Cell Discov. 2019 Jun 25;5:33
pubmed: 31263570
Sci China Life Sci. 2020 Jul 28;:
pubmed: 32737853
Cells. 2018 Mar 15;7(3):
pubmed: 29543760
Mol Cancer Ther. 2017 Nov;16(11):2586-2597
pubmed: 28835384
Zool Res. 2020 Sep 18;41(5):495-502
pubmed: 32808517